← Back to Search
Photobiomodulation (PBM) for Age-Related Macular Degeneration
This trial is a continuation of a previous study on the use of photobiomodulation in people with dry age-related macular degeneration. It is open to participants from multiple centers.
Inclusion CriteriaYou may be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the current number of individuals being enrolled in this clinical trial?
"To complete this clinical trial, a total of 75 eligible patients are required to participate. Patients from different regions, including Cherry Hill in New jersey (specifically at Mid Atlantic Retina) and Altamonte Springs in Florida (particularly at the Florida Eye Clinic), can take part in this study."
Are there any available vacancies for patient participation in this clinical trial?
"Indeed, the information available on clinicaltrials.gov affirms that this trial is actively seeking individuals to participate. The study was initially posted on October 25th, 2023, and has been recently updated on January 19th, 2024. There are a total of nine locations where they aim to enroll 75 patients in this study."
In how many different medical centers can patients access this clinical trial?
"Among the nine operational sites for this clinical trial, notable locations include Mid Atlantic Retina in Cherry Hill, Florida Eye Clinic in Altamonte Springs, and Retina Vitreous Associates Medical Group in Beverly Hills. Additionally, there are another six locations participating in the study."